Sort   by:  
 Page size 
UnknownDesign and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Not available
S-EPMC6888890 | biostudies-literature
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Not available
S-EPMC9271031 | biostudies-literature
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Not available
S-EPMC9862372 | biostudies-literature
UnknownOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Not available
S-EPMC10278789 | biostudies-literature
UnknownValidation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery.
Not available
S-EPMC8855527 | biostudies-literature
UnknownGlobal Burden of Cardiovascular Diseases and Risks, 1990-2022.
Not available
S-EPMC7615984 | biostudies-literature
UnknownThe global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12687902 | biostudies-literature
UnknownGlobal age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535839 | biostudies-literature
UnknownBurden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840 | biostudies-literature
Sort   by:  
 Page size